Lakefront

Lakefront Biosciences is a precision oncology company dedicated to developing next-generation small molecule therapies for cancer patients. The company was founded by the core scientific team responsible for the success of Turning Point Therapeutics, bringing significant expertise in structure-based drug design. Lakefront focuses on designing highly potent and selective inhibitors to address clinical limitations and resistance mutations in existing treatments. Currently in the pre-clinical phase, the firm is advancing a pipeline of candidates targeting key oncogenic drivers in solid tumors. The company leverages its proprietary insights into protein-ligand interactions to create differentiated therapeutic options. Headquartered in San Diego, Lakefront is positioned as a fast-moving innovator in the kinase inhibitor space.